NCT03481803 - A Phase IIa Study With Escalating Dose of MS1819-SD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 27, 2017

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions

Chronic PancreatitisDistal Pancreatectomy

Interventions

DRUG

MS1819-SD

Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.

Trial Locations (6)

4740

Mackay Institute of Research and Innovation, Mackay

5000

CMAX, Adelaide

6009

Linear Research, Perth

6242

P3 Research, Wellington

8011

Christchurch Clinical Studies Trust, Christchurch

13385

Hôpital Timone Adulte (CIC-CPCET), Marseille